AVTX - Avalo Therapeutics, Inc. Stock Price, Fair Value and News

9.92USD+0.28 (+2.90%)Delayed

Market Summary

USD9.92+0.28

Delayed

2.90%

AVTX Stock Price

View Fullscreen

AVTX RSI Chart

AVTX Valuation

Market Cap

10.3M

Price/Earnings (Trailing)

-0.07

Price/Sales (Trailing)

5.33

EV/EBITDA

0.71

Price/Free Cashflow

-0.38

AVTX Price/Sales (Trailing)

AVTX Profitability

EBT Margin

-7425.47%

Return on Equity

126.96%

Return on Assets

-115.48%

Free Cashflow Yield

-261.52%

AVTX Fundamentals

AVTX Revenue

Revenue (TTM)

1.9M

Rev. Growth (Yr)

-36.27%

Rev. Growth (Qtr)

141.95%

AVTX Earnings

Earnings (TTM)

-142.9M

Earnings Growth (Yr)

-1.1K%

Earnings Growth (Qtr)

-1.4K%

Breaking Down AVTX Revenue

Last 7 days

-8.6%

Last 30 days

-27.2%

Last 90 days

122.4%

Trailing 12 Months

-98.7%

How does AVTX drawdown profile look like?

AVTX Financial Health

Current Ratio

0.52

Debt/Equity

-0.13

Debt/Cashflow

-1.88

AVTX Investor Care

Shares Dilution (1Y)

1780.16%

Diluted EPS (TTM)

-121.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	14.0M	10.0M	6.0M	1.9M
2022	6.1M	3.8M	17.4M	18.1M
2021	4.4M	6.4M	6.7M	5.4M
2020	6.9M	6.9M	5.8M	6.7M
2019	7.0M	6.9M	6.8M	6.8M
2018	32.2M	36.5M	15.6M	7.0M
2017	1.5M	10.3M	19.1M	27.8M
2016	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Avalo Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 27, 2023	armistice capital, llc	sold	-486,888	0.5194	-937,404	-
Jun 26, 2023	caissa capital management ltd.	bought	-113,026	0.62	-182,300	-
Jun 26, 2023	armistice capital, llc	sold	-1,682,010	0.6125	-2,746,140	-
Jun 26, 2023	caissa capital management ltd.	bought	-917,153	0.6433	-1,425,700	-
Jun 20, 2023	caissa capital management ltd.	bought	8,288	4.1444	2,000	-
Jun 16, 2023	caissa capital management ltd.	bought	11,714	3.9048	3,000	-
Jun 15, 2023	caissa capital management ltd.	bought	11,640	3.6837	3,160	-
Jun 14, 2023	caissa capital management ltd.	bought	20,874	3.479	6,000	-
Jun 13, 2023	caissa capital management ltd.	bought	33,439	3.8216	8,750	-
Jun 12, 2023	caissa capital management ltd.	bought	9,316	4.3352	2,149	-

Which funds bought or sold AVTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-11.36	448	848	-%
May 15, 2024	ADAR1 Capital Management, LLC	new	-	130,500	130,500	0.03%
May 15, 2024	Ikarian Capital, LLC	new	-	43,422,400	43,422,400	4.53%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-7.13	19,599	35,670	-%
May 15, 2024	Sio Capital Management, LLC	new	-	220,784	220,784	0.07%
May 15, 2024	Royal Bank of Canada	added	133	6,000	7,000	-%
May 14, 2024	Affinity Asset Advisors, LLC	new	-	217,500	217,500	0.03%
May 14, 2024	OLD POINT TRUST & FINANCIAL SERVICES N A	new	-	22.00	22.00	-%
May 13, 2024	UBS Group AG	added	385,550	167,740	167,758	-%
May 13, 2024	NATIXIS	reduced	-45.44	11,358	54,636	-%

Are Funds Buying or Selling AVTX?

Are funds buying AVTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVTX

No. of Funds

Unveiling Avalo Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	allostery investments lp	7.6%	78,255	SC 13G
Apr 23, 2024	emerald bioventures, llc	5.6%	58,346	SC 13G
Apr 05, 2024	deep track capital, lp	9.99%	114,775	SC 13G
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	0.0%	0	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	0.3%	2,500	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	4.9%	42,100	SC 13G/A
Feb 14, 2024	great point partners llc	0.26%	2,085	SC 13G/A
Jun 29, 2023	caissa capital management ltd.	0%	0	SC 13G/A
Jun 28, 2023	armistice capital, llc	4.7%	588,850	SC 13D/A
Apr 19, 2023	caissa capital management ltd.	9.81%	1,292,700	SC 13G/A

Recent SEC filings of Avalo Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 13, 2024	SC 13G	Major Ownership Report
Apr 23, 2024	SC 13G	Major Ownership Report
Apr 09, 2024	D	D
Apr 05, 2024	SC 13G	Major Ownership Report
Apr 03, 2024	3	Insider Trading
Apr 03, 2024	3	Insider Trading
Apr 03, 2024	3	Insider Trading
Mar 29, 2024	10-K	Annual Report

Peers (Alternatives to Avalo Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Avalo Therapeutics, Inc. News

Latest updates

Avalo Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	571,000	236,000	643,000	769,500	896,000	14,949,000	1,033,000	1,173,000	219,500	1,350,000	3,355,000	473,000	1,496,500	1,111,000	1,338,000	2,754,000	580,808	2,201,232	1,391,942	2,576,369
Costs and Expenses	298.2%	32,767,000	8,229,000	3,986,000	7,793,000	9,267,000	9,750,500	10,854,000	12,861,000	22,026,000	18,182,000	17,813,000	20,484,000	31,053,000	17,835,000	14,388,000	13,153,000	34,167,000	6,303,643	5,062,795	3,940,011	7,581,311
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,328,632	10,425,250	12,434,215
S&GA Expenses	-100.0%	-	2,675,500	2,490,000	2,427,000	2,708,000	2,959,000	3,284,000	2,784,000	11,684,000	8,437,000	5,926,000	7,404,000	435,000	549,000	462,000	653,000	677,000	547,701	214,207	325,861	396,276
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,401,189
EBITDA Margin	-380.5%	-73.54	-15.31	-5.11	-2.19	-1.90	-2.13	-2.64	-17.42	-13.74	-13.97	-11.38	-11.28	-18.01	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	486,000	735,000	704,000	675,000	599,000	826,000	831,000	789,000	796,000	-	-	-	-	-	-	262,500	262,500	262,500	262,500
Income Taxes	177.8%	7,000	-9,000	8,000	7,000	8,000	8,500	5,000	5,000	9,000	-11,500	-	-200,000	11,000	-141,000	3,000	-500,000	-2,200,000	-30,504	121,640	100,000	100,000
Earnings Before Taxes	-1383.2%	-121,283,000	-8,177,000	-5,220,000	-8,186,000	-9,947,000	-9,803,500	3,197,000	-12,982,000	-22,042,000	-	-17,463,000	-17,373,000	-30,563,000	-	-13,258,000	-13,280,000	-24,312,000	-	-2,808,852	-2,490,747	-5,031,702
EBT Margin	-353.1%	-74.25	-16.39	-5.57	-2.48	-2.11	-2.31	-2.84	-18.50	-14.34	-14.57	-11.78	-11.57	-18.43	-	-	-	-	-	-	-	-
Net Income	-1384.9%	-121,290,000	-8,168,000	-5,228,000	-8,193,000	-9,955,000	-9,812,000	3,192,000	-12,987,000	-22,051,000	-19,196,000	-17,395,000	-17,105,000	-30,680,000	-15,643,000	-13,459,000	-13,281,000	-21,117,000	1,621,054	-4,016,454	-6,223,099	-7,454,048
Net Income Margin	-353.0%	-74.26	-16.40	-5.57	-2.48	-2.11	-2.31	-2.94	-18.97	-12.42	-15.63	-12.11	-11.95	-16.54	-	-	-	-	-	-	-	-
Free Cashflow	-124.2%	-6,200,000	-2,766,000	-6,814,000	-11,048,000	-10,052,000	-3,940,000	5,687,000	-12,526,000	-16,067,000	-17,110,000	-16,371,000	-19,187,000	-18,337,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	489.4%	124	21.00	29.00	24.00	36.00	33.00	37.00	32.00	62.00	80.00	95.00	64.00	63.00	44.00	59.00	69.00	44.00	36.00	57.00	60.00	75.00
Current Assets	1224.8%	111	8.00	13.00	8.00	19.00	16.00	19.00	15.00	44.00	62.00	77.00	47.00	46.00	26.00	41.00	50.00	25.00	18.00	13.00	14.00	27.00
Cash Equivalents	1387.7%	110	7.00	10.00	6.00	17.00	13.00	17.00	11.00	38.00	55.00	72.00	40.00	38.00	19.00	33.00	45.00	6.00	4.00	5.00	9.00	16.00
Inventory	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	1.00	1.00	1.00	2.00	1.00
Goodwill	0%	11.00	11.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	16.00	16.00	16.00
Liabilities	1542.3%	225	14.00	15.00	31.00	43.00	44.00	39.00	38.00	56.00	57.00	55.00	42.00	30.00	19.00	21.00	19.00	19.00	15.00	39.00	42.00	52.00
Current Liabilities	4570.9%	216	5.00	6.00	22.00	23.00	22.00	18.00	15.00	18.00	20.00	19.00	22.00	26.00	15.00	17.00	15.00	15.00	12.00	17.00	19.00	28.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.00	14.00	14.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.00	14.00	14.00
Shareholder's Equity	-1640.8%	-112	7.00	15.00	-	-6.27	-10.91	-	-	6.00	23.00	40.00	22.00	33.00	25.00	39.00	51.00	26.00	21.00	18.00	18.00	23.00
Retained Earnings	-36.2%	-456	-335	-326	-321	-313	-303	-294	-297	-284	-262	-243	-225	-208	-177	-162	-148	-135	-114	-115	-111	-105
Additional Paid-In Capital	0.4%	344	342	341	315	307	293	292	291	290	285	283	247	242	202	201	199	161	135	134	130	129
Shares Outstanding	29.0%	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	5.00	-	-	-	32.00	-	-	-	184	-	-	-	112	-	-	-	81.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-124.2%	-6,200	-2,766	-6,814	-11,048	-10,052	-3,940	5,726	-12,470	-16,067	-17,099	-16,290	-19,187	-18,316	-14,375	-11,870	-8,555	-5,739	-1,680	-7,615	-6,717	-3,121
Share Based Compensation	-18.9%	629	776	953	893	855	843	731	668	5,312	1,892	1,758	3,074	1,448	1,437	1,447	2,786	1,116	590	819	527	597
Cashflow From Investing	-	356	-	-	-	-133	-	-39.00	-56.00	-	-11.00	-81.00	-	-21.00	-391	-63.00	12,837	-1,251	-180	-5.08	-90.96	-165
Cashflow From Financing	10861100.0%	108,612	1.00	10,695	598	13,748	82.00	-	-14,781	-	76.00	47,643	21,218	37,825	200	1.00	35,485	9,098	136	3,510	97.00	8,817
Buy Backs	-	-	-	-	3,640	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AVTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Revenues:

Total revenues, net

$ 0

$ 475

Operating expenses:

Cost of product sales

(80)

551

Research and development

2,116

6,008

Acquired in-process research and development

27,538

General and administrative

3,193

2,708

Total operating expenses

32,767

9,267

Total operating income (loss)

(32,767)

(8,792)

Other expense:

Excess of warrant fair value over private placement proceeds

(79,276)

Private placement transaction costs

(9,220)

Change in fair value of derivative liability

(120)

(180)

Interest income, net

100

(949)

Other expense, net

(26)

Total other expense, net

(88,516)

(1,155)

Loss before taxes

(121,283)

(9,947)

Income tax expense

Net loss

(121,290)

(9,955)

Comprehensive loss

$ (121,290)

$ (9,955)

Net loss per share of common stock, basic (in dollars per share)

^[1]

$ (141)

$ (204)

Net loss per share of common stock, diluted (in dollars per share)

^[1]

$ (141)

$ (204)

Product revenue, net

Revenues:

Total revenues, net

$ 0

$ 475

[1]	Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-240 reverse stock split effected on December 28, 2023. See Note 1 for details.

AVTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 110,177	$ 7,415
Other receivables	35	136
Prepaid expenses and other current assets	997	843
Restricted cash, current portion	4	1
Total current assets	111,213	8,395
Property and equipment, net	1,882	1,965
Goodwill	10,502	10,502
Restricted cash, net of current portion	131	131
Total assets	123,728	20,993
Current liabilities:
Accounts payable	916	446
Accrued expenses and other current liabilities	7,383	4,172
Warrant liability	194,901	0
Contingent consideration	12,500	0
Total current liabilities	215,700	4,618
Royalty obligation	2,000	2,000
Deferred tax liability, net	162	155
Derivative liability	5,670	5,550
Other long-term liabilities	1,281	1,366
Total liabilities	224,813	13,689
Mezzanine equity:
Temporary equity, values issued	11,457	0
Stockholders’ (deficit) equity:
Common stock—$0.001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 1,034,130 and 801,746 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1	1
Additional paid-in capital	343,881	342,437
Accumulated deficit	(456,424)	(335,134)
Total stockholders’ (deficit) equity	(112,542)	7,304
Total liabilities, mezzanine equity and stockholders’ (deficit) equity	123,728	20,993
Series C Preferred Stock
Mezzanine equity:
Temporary equity, values issued	11,457	0
Series D Preferred Stock
Mezzanine equity:
Temporary equity, values issued	0	0
Series E Preferred Stock
Mezzanine equity:
Temporary equity, values issued	$ 0	$ 0

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

CEO	Dr. Garry A. Neil M.D.
WEBSITE	avalotx.com
INDUSTRY	Biotechnology
EMPLOYEES	20

Avalo Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Avalo Therapeutics, Inc.? What does AVTX stand for in stocks?

AVTX is the stock ticker symbol of Avalo Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avalo Therapeutics, Inc. (AVTX)?

As of Fri May 17 2024, market cap of Avalo Therapeutics, Inc. is 10.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVTX stock?

You can check AVTX's fair value in chart for subscribers.

What is the fair value of AVTX stock?

You can check AVTX's fair value in chart for subscribers. The fair value of Avalo Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avalo Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avalo Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether AVTX is over valued or under valued. Whether Avalo Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Avalo Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVTX.

What is Avalo Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AVTX's PE ratio (Price to Earnings) is -0.07 and Price to Sales (PS) ratio is 5.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVTX PE ratio will change depending on the future growth rate expectations of investors.